---
layout: default
title: Elsa Bernard
---

<div id="toptitle">
	<h1>{{ page.title }}</h1>
</div>


<table class="imgtable">
	<tr>
		<td>
			<img src="images/elsab.jpg" alt="a picture of Elsa" width="150px" />&nbsp;
		</td>

		<td align="left"><p>Postdoctoral researcher at <a href="https://www.mskcc.org/">Memorial Sloan Kettering Cancer Center</a>, New York, USA.
			<br /></p>

			<br />
			I am a postdoctoral research fellow in the Department of Epidemiology and Biostatistics of MSKCC under the mentorship of <a href="https://www.mskcc.org/research-areas/labs/elli-papaemmanuil">Elli Papaemmanuil</a>. I obtained my PhD in Bioinformatics in September 2016 from the <a href="http://cbio.mines-paristech.fr/">Center for Computational Biology</a> at <a href="https://en.wikipedia.org/wiki/Mines_ParisTech">MinesParistech</a> under the supervision of <a href="http://members.cbio.mines-paristech.fr/~jvert/">Jean-Philippe Vert</a>.

			<h2>Contact</h2>
			<p>MSKCC - Papaemmanuil Lab<br />
			Zuckerman Research Center<br />
			417 East 68th Street<br />
			New York, NY 10065<br />
			bernare2 (at) mskcc [dot] org
		</td>
	</tr>
</table>

<h2>Research interests</h2>
<p>
My research interests broadly lie in the development of statistically sound methods to address molecular biology questions and to contribute to personalized medicine in cancer research.
More specifically, I am interested in:
<li> cancer genomics
</li> 
<li> personalized cancer medicine
</li>
<li> (alternative) splicing
</li>
<li> machine learning & predictive models
</li>
<br>
I am currently working on building patient stratification rules and diagnosis and prognosis models for
<a href="https://en.wikipedia.org/wiki/Myelodysplastic_syndrome">myelodysplastic syndrome (MDS)</a> using DNA somatic mutations and clinical data. For that purpose I am leading the analysis of the international <a href="https://www.mskcc.org/research-areas/labs/elli-papaemmanuil/international-working-group-prognostication-mds">IWG</a> project.

I am also investigating the transcriptomic effect of recurrent MDS patients' mutations across hematopoetic cell lineages.
<p>
